Efficacy Of Technetium[99tc] Methylenediphosphonate Treated In The Type 2 Diabetic Patients With Postmenopausal Osteoporosis

Objective:To explore the Efficacy of Technetium[99Tc] Methylenediphosphonate combined with administration of calcium tablet and calcitriol, treated in the type 2 diabetic patients with postmenopausal osteoporosis. Method:we recruited 31 type 2 diabetic patients nequivocally diagnosed of postmenopausal osteoporosis as treatment group (race: Han=19, Urger=12), who were given Technetium[99Tc] Methylenediphosphonate intravenously Every day. At same time, matched with age, duration of type 2 diabetes, duration of postmenopause, we set up a control group (N=28, race: Han=14, Urger=14). calcium tablet and calcitriol were administered as basic therapy of two groups. The therapy went on for 6 months. Evaluating indexes, including bone mineral density(BMD), alkaline phosphatase(ALP) and bone mineral metabolism indexes, were compared between pre- and post-therapy within groups as well as between two groups. Serum indexes of liver function and renal function were also measured for security. Result:after 6 months, the treatment group is statistically superior to control group in each part of mean BMD (P<0.05), and amelioration rate is 93.5%. the BMD of 1/3 point of left forearm, Lendenwirbel, neck of femur raise 4.3%, 2.8%,3.2% respectively compared with pre-therapy period in treatment group, and ALP is much lower, which has statistic significance. Liver function, renal function have not been disturbed in either group during treatment.Conclusion:It is safe and effective for Technetium[99Tc] Methylenediphosph- onate with combination of calcium tablet and calcitriol in the treatment of type 2 diabetic patients with postmenopausal osteoporosis.